EUVIMEDEUVIMED entdecken
Crossref

Pharmacokinetics of intravenous piperacillin/tazobactam among patients with peritoneal dialysis-associated peritonitis

Taweesak Maneerot iD, Suwikran Wongpraphairot, Aroonrut Lucksiri, Sutep Jaruratanasirikul, Weerachai Chaijamorn iD, Nanthawut Ninwisut, Uraiwan Parinyasiri, Yuttitham Suteeka, Sutthiporn Pattharachayakul

Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis · 2025

DOI: 10.1177/08968608241241449 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, 2025. Verfasst von Taweesak Maneerot und 8 weiteren Autor:innen. Beteiligte Einrichtung: The College of Pharmacotherapy of Thailand, The Pharmacy Council, Nonthaburi, Thailand. Hauptthemen laut MEDLINE: Peritonitis, Piperacillin, Anti-Bacterial Agents, Penicillanic Acid. Die Arbeit nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Currently, pharmacokinetic information on intravenous (IV) piperacillin/tazobactam in patients with peritoneal dialysis-associated peritonitis (PD peritonitis) is limited. This study employed a prospective single-dose pharmacokinetic design to assess the pharmacokinetics of IV piperacillin/tazobactam in these patients. Four patients with PD peritonitis who received an IV loading dose of 4000 mg/500 mg piperacillin/tazobactam were enrolled in this study. The concentrations of piperacillin and tazobactam in plasma, peritoneal dialysis fluid (PDF) and urine were determined by high-performance liquid chromatography. Non-compartmental methods were used for pharmacokinetic analysis. During a 6-h dwell time for chronic ambulatory peritoneal dialysis (CAPD), 9.23 ± 4.01% of the piperacillin was recovered in the PDF. This result is greater than that observed in patients without peritonitis in prior research. Piperacillin’s PD clearance (CL PD ), steady-state volume of distribution ( Vss) and terminal half-life ( t 1/2 ) were 5.79 ± 2.55 mL/min, 24.35 ± 11.26 L and 5.74 ± 1.53 h, respectively. These values are also higher than those of patients without peritonitis in a prior study. Eight hours following the loading dosage, the plasma and PDF piperacillin concentrations of all patients (98.25 ± 26.03 and 52.70 ± 22.99 mg/L, respectively) surpassed the Pseudomonas aeruginosa and Enterobacterales Clinical and Laboratory Standards Institute susceptible breakpoints. In summary, the CL PD , Vss and t 1/2 for piperacillin were found to be greater in patients with PD peritonitis than in CAPD patients without peritonitis when compared with the results of a previous study. The IV loading dose of 4000 mg/500 mg piperacillin/tazobactam is sufficient to treat peritonitis caused by susceptible P. aeruginosa and Enterobacterales. The multiple-dose pharmacokinetics of IV piperacillin and tazobactam in this specific patient group should be further investigated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PeritonitisPiperacillinAnti-Bacterial AgentsPenicillanic AcidPeritoneal DialysisHumansMaleMiddle AgedFemaleProspective StudiesPiperacillin, Tazobactam Drug CombinationAgedKidney Failure, ChronicAdultInfusions, Intravenous

Stichwörter der Autor:innen

Peritoneal dialysisperitoneal dialysis-associated peritonitispharmacokineticspiperacillin/tazobactam

Substanzen

PiperacillinAnti-Bacterial AgentsPiperacillin, Tazobactam Drug CombinationPenicillanic Acid

Autor:innen und Institutionen

  • The College of Pharmacotherapy of Thailand, The Pharmacy Council, Nonthaburi, Thailand.
  • Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Songkhla, Thailand.
  • Division of Nephrology, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
  • Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Thailand.
  • Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
  • Faculty of Pharmacy, Siam University, Bangkok, Thailand.

ORCID-Profile: Taweesak Maneerot, Weerachai Chaijamorn

Zitieren

APA

Maneerot, T., Wongpraphairot, S., Lucksiri, A., Jaruratanasirikul, S., Chaijamorn, W., Ninwisut, N., Parinyasiri, U., Suteeka, Y., & Pattharachayakul, S. (2025). Pharmacokinetics of intravenous piperacillin/tazobactam among patients with peritoneal dialysis-associated peritonitis. Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis. https://doi.org/10.1177/08968608241241449

Vancouver

Maneerot T, Wongpraphairot S, Lucksiri A, Jaruratanasirikul S, Chaijamorn W, Ninwisut N, et al. Pharmacokinetics of intravenous piperacillin/tazobactam among patients with peritoneal dialysis-associated peritonitis. Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis. 2025. doi:10.1177/08968608241241449

BibTeX
@article{Maneerot2025,
  author = {Maneerot, Taweesak and Wongpraphairot, Suwikran and Lucksiri, Aroonrut and Jaruratanasirikul, Sutep and Chaijamorn, Weerachai and Ninwisut, Nanthawut and Parinyasiri, Uraiwan and Suteeka, Yuttitham and Pattharachayakul, Sutthiporn},
  title = {Pharmacokinetics of intravenous piperacillin/tazobactam among patients with peritoneal dialysis-associated peritonitis},
  journal = {Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis},
  year = {2025},
  doi = {10.1177/08968608241241449}
}
Kostenlos starten →